Transcript Slide Set 1

Update on New Fluoroquinolones
Boxed Warning & Increasing
Fluoroquinolone Resistance
JENNIFER DOAN, PHARM. D
PHARMACY RESIDENT, UNITY HEALTH
SEPTEMBER 30, 2016
1
Learning Objectives
 Recognize potential fluoroquinolone toxicities that may
occur with systemic fluoroquinolone use
 Discuss the efficacy of systemic fluoroquinolone use for the
following indications:
 Acute bacterial sinusitis
 Acute bacterial exacerbation of chronic bronchitis
 Uncomplicated urinary tract infections
 Understand increasing resistance with fluoroquinolone use
2
Fluoroquinolones
 Mechanism of Action: Inhibition of DNA replication by binding to
topoisomerase II (DNA gyrase) and topoisomerase IV
 FDA-Approved Indications








Community-acquired pneumonia
Nosocomial pneumonia
Chronic bronchitis (acute bacterial exacerbation)
Acute bacterial rhinosinusitis
Prostatitis
Urinary tract infection (uncomplicated or complicated)
Acute pyelonephritis
Skin or skin structure infections (uncomplicated or complicated)
3
Potential Adverse Effects
 Photosensitivity
 Hypersensitivity
 QT prolongation
 Peripheral neuropathy
 Tendinitis or tendon rupture
 CNS effects
 Myasthenia gravis exacerbation
4
Photosensitivity & Hypersensitivity
 Photosensitivity/Phototoxicity: Moderate to severe
photosensitivity/phototoxicity reactions, the latter of which
may manifest as exaggerated sunburn reactions involving
areas exposed to light, can be associated with the use of
fluoroquinolones after sun or UV light exposure
 Hypersensitivity: Serious and potentially fatal anaphylactic
reactions may occur in patients who receive fluoroquinolone
therapy
5
QT-Interval Prolongation
 Fluoroquinolones may lead to prolonged QT intervals due to
inhibition of potassium channels
 Prolonged QTc interval >500 milliseconds is associated with an
increased risk for Torsades de Pointes, a life-threatening cardiac
arrhythmia
 Although QT prolongation is not common, caution should be
warranted with fluoroquinolone use when being administered
with other agents that cause QT prolongation
6
Peripheral Neuropathy
 Peripheral neuropathy: Nerve
disorder that occurs in the arms or legs
 Symptoms: Pain, tingling, numbness,
weakness
 These reactions may occur at any
time during treatment and may persist
for months to years after the agent is
discontinued
7
Tendinitis or Tendon Rupture
 Symptoms: Pain, swelling, inflammation of a
tendon or tendon rupture
 The risk of developing tendinitis or tendon
rupture is further increased in:
 Patients who are older than 60 years old
 Patients who are taking corticosteroid drugs
 Patients who are kidney, heart, and lung
transplant recipients
8
CNS Effects
 Fluoroquinolones have potential for CNS adverse effects such
as:
 Depression, suicidal thoughts
 Hallucinations
 Confusion
 Anxiety
 Mild headache
 Drowsiness or insomnia
 Seizures – rare but may still occur (especially in patients with a
lower seizure threshold)
9
Myasthenia Gravis
Myasthenia gravis is a disease characterized by
skeletal muscle weakness and may involve
symptoms such as:
 Drooping eyelid, blurred or double vision
 Slurred speech, difficulty chewing/swallowing
 Weakness in arms/legs
 Case reports revealed that fluoroquinolone
exposure may lead to life-threatening
myasthenia gravis exacerbations in patients with
underlying disease
10
November 2015
 Antimicrobial Drugs Advisory
Committee and Drug Safety and Risk
Management Advisory Committee
met to discuss the efficacy and safety
of fluoroquinolone use in cases of
acute bacterial sinusitis, acute
bacterial exacerbation of chronic
bronchitis, and uncomplicated urinary
tract infection
 The suggestion of stronger warnings
for systemic fluoroquinolones was
discussed
11
Literature Review Before FDA-Approval
 Acute Bacterial Exacerbation of Chronic Bronchitis: The FDA reviewed 15
placebo-controlled trials and found that only six of the trials revealed statistically
significant results
 Fluoroquinolone use may be considered in patients who have moderate-tosevere acute bacterial exacerbation of chronic bronchitis
 Acute Bacterial Sinusitis: The FDA reviewed 20 published placebo-controlled
trials and found that only six of the trials revealed statistically significant results
 Lack of clinical criteria to differentiate between bacterial and viral acute
rhinosinusitis has led to inappropriate antibacterial therapy
 Uncomplicated Urinary Tract Infection: The FDA reviewed 5 prospective,
randomized, controlled trials for patients in an outpatient setting
 A good proportion of patients who received placebo treatment still achieved
microbiological eradication
12
New Fluoroquinolone Boxed Warning
Fluoroquinolones should be reserved for use in
patients who have no other treatment options for
acute bacterial sinusitis, acute bacterial
exacerbation of chronic bronchitis, and
uncomplicated urinary tract infections
13
Excessive Fluoroquinolone Use Consequences
 Excessive use of fluoroquinolone agents had led to widespread
resistance among bacterial pathogens
 Resistance develops by either mutation or acquisition of novel
genetic information
 Fluoroquinolone resistance has been demonstrated in urinary
infections, respiratory infections, gastrointestinal tract infections,
skin and soft-tissue and bone and joint infections, sexually
transmitted diseases, and ulcers
14
Common Organisms with Potential for Resistance
Burkholderia cepacia
Mycoplasma pneumoniae
Campylobacter jejuni
Neisseria gonorrhoeae
Chlamydia trachomatis
Pseudomonas aeruginosa
Enterococcus faecium
Staphylococcus aureus
Escherichia coli
Streptococcus pneumoniae
Klebsiella pneumoniae
15
Antibiogram Chart
16
Preserving Fluoroquinolone Efficacy
 Develop an evidence-based approach to antimicrobial
selection
 Assess the appropriateness of drug utilization by reviewing
the activity of these agents and the patient’s disease state
 Ensure that patients who are candidates for fluoroquinolone
use, are provided an indicated dose for an appropriate duration
of time
17
Question
The new FDA boxed warning opposes the use of fluoroquinolones in all cases of ABS, ACBECB,
and uUTI due to the disabling and potentially permanent adverse effects that are associated
with systemic fluoroquinolone use.
A. True
B. False
18
References
 Ahovuo-Saloranta A, Rautakorpi UM, Borisenko OV, Liira H, Williams JW Jr. Makela M. Antibiotics for acute maxillary sinusitis in adults.
Cochrane Database Syst Rev. 2014 Feb 11;(22):CD000243. doi:10.1002/14651858.CD0000243.pub3
 Alonso Martínez JL, Rubio Obanos MT, Sampériz Legarre AL, Escolar Castellón F, Carrasco del Amo ME. Antibiotic treatment for acute
episodes of chronic obstructive pulmonary disease. An Med Interna. 1992;9(8):377-80
 Axelsson A, Chidekel N, Grebelious N, Jensen C. Treatment of acute maxillary sinusitis. A comparison of four different methods. Acta
Otolaryngol. 1970;70(1):71-6
 Baquero F. Antibiotic resistance in Spain: What can be done? Task Force of the General Directions for Health Planning of the Spanish
Ministry of Health. Clin Infect Dis. 1996;23:819-23.
 Chou HW, Wang JL, Chang CH, Lai CL, Lai MS, Chan KA. Risks of cardiac arrhythmia and mortality among patients using new-generation
macrolides, fluoroquinolones, and beta-lactam/beta-lactamase inhibitors: a Taiwanese nationwide study. Clin Infect Dis 2015;60:566577.
 Etminan M, Brophy JM, Samii A. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study.
Neurology. 2014 Sep 30;83(14):1261-3.
 FDA Briefing Document. Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management
Advisory Committee.
 Gerdin DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial
resistance problem. Clin Infect Dis. 2004;38(5):646-8.
19
References
 Hadley JA, Mӧsges R, Desrosiers M, et al. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis. The
Laryngoscope. 2010;120(5):1057-1062
 IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults.
 Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports
from the US FDA adverse event reporting system and a literature review. Drug Saf. 2001 Oct 1;34(10):839-47.
 Karageorgopoulos DE, Giannopoulou KP, Grammatikos AP, et al. Fluoroquinolones compared with β-lactam antibiotics for the treatment
of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ. 2008;178(7):845-54.
 Lexi-Comp, Inc. (Lexi-Drugs® ). Lexi-Comp, Inc. (accessed Aug 22, 2016).
 Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin Infect Dis. 1999;28(2):352-361.
 Manresa F, Blavia R, Martin R, Liñares J, Rodriguez B, Verdaguer R. Antibiotics for exacerbations of chronic bronchitis. Lancet.
1987;2(8555):394-5.
 McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect
Dis. 2003 June;9(6):730-3.
 Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacoth. 2007;41(11):1859-1866.
 Nouria S, Marghi S, Belghith M, et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring
mechanical ventilation: a randomised placebo controlled trial. Lancet. 2001;358(9298):2020-25
20
References
 Owens RC, Ambrose PG. Antimicrobial safety: Focus on fluoroquinolones. Clinical Infectious Diseases. 2005;41(Supplement 2):S144S157.
 Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam med
2014;12(2):121-127.
 Saux NL. The treatment of acute bacterial sinusitis: No change is good medicine. CMAJ. 2008 Mar 25;178(7): 865-866.
 Seeger JD, West WA, Fife D, Noel GJ, Johnson LN, Walker AM. Achilles tendon rupture and its association with fluoroquinolone
antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf. 2006;15(11):784-792.
 U.S Food and Drug Administration.
 van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH. Increased risk of Achilles tendon rupture with
quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med. 2003;163(15):1801-1807.
 Wilton LV, Pearce GL, & Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by
observational cohort studies. Br J Clin Pharmacol. 1996;41(4):277-284.
21